Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP

Study Purpose:

Patient with amyotrophic lateral sclerosis (ALS) having anti-NRIP autoantibody showed titer-dependent detrimental Effects. Plasmapheresis might benefit this subgroup of patients via removal of anti-NRIP autoantibody

Study Status:

Not yet recruiting

Disease:

Amyotrophic Lateral Sclerosis , Plasmapheresis

Study Type:

Interventional

Type of Intervention:

Procedure

Intervention Name:

Plasmapheresis

Placebo:

No

Phase:

N/A

Study Chair(s)/Principal Investigator(s):

N/A

Clinicaltrials.gov ID:

NCT05562960

Neals Affiliated?

No

Coordinating Center Contact Information

Li-Kai Tsai, MD., Ph.D. / email hidden; JavaScript is required / 886-2-23123456

Study Sponsor:

National Taiwan University Hospital

Estimated Enrollment:

20

Estimated Study Start Date:

11 / 01 / 2022

Estimated Study Completion Date:

03 / 31 / 2025

Posting Last Modified Date:

10 / 05 / 2022

Date Study Added to neals.org:

10 / 03 / 2022

Minimum Age:

20 Years

Maximum Age:

N/A

Inclusion Criteria:

1. Patients with amyotrophic lateral sclerosis (ALS) at the age more than 20 years and having plasma anti-NRIP autoantibody.

2. Agree to receive plasmapheresis intervention.

3. Agree to participate in the trial and receive serial examinations and follow up.

Exclusion Criteria:

1. Patients without plasma anti-NRIP autoantibody.

2. Patients requiring permanent ventilator support for ALS progression.

3. Not able to receive plasmapheresis or trial-related examinations.

4. Under pregnancy.

5. Blood fibrinogen level less than 50 mg/dl.

6. Specific ALS subtypes, including primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, or flail leg syndrome.